Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, a phase 3 trial showed that the BCMA‐targeting bispecific antibody teclistamab significantly improved progression‐free survival and overall survival in patients with relapsed or refractory multiple myeloma who received one to three previous lines of therapy. In addition, adjuvant nivolumab fails to improve disease‐free survival in patients with resected NSCLC, and perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer.

Authors

Publication Details

Journal
Cancer
Published
2026-11-14
DOI
https://doi.org/10.1002/cncr.70639
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma

Leah Lawrence
Cancer
Multiple Myeloma Research and Treatments
article

Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma

Leah Lawrence
article en

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, a phase 3 trial showed that the BCMA‐targeting bispecific antibody teclistamab significantly improved progression‐free survival and overall survival in patients with relapsed or refractory multiple myeloma who received one to three previous lines of therapy. In addition, adjuvant nivolumab fails to improve disease‐free survival in patients with resected NSCLC, and perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer.

CancerVol. 132(22)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon